Registry of Patients Being Treated With Norditropin, Recombinant Human Growth Hormone
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Somatrogon (Primary)
- Indications Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
- Focus Therapeutic Use
- Acronyms ANSWER
- Sponsors Novo Nordisk
- 20 Mar 2018 Results (n=304) assessing the long term safety and effectiveness data on adult patients with growth hormone deficiency treated with Norditropin (somatropin), presented at The 100th Annual Meeting of the Endocrine Society.
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
- 11 Apr 2017 Status changed from recruiting to completed.